Latest news and press releases about Neurocrine Biosciences, Inc. (NBIX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages.
Price
| Price | $141.84 |
| Market Cap | $14.3B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 20.31 |
| Price / Book | 3.92 |
| EV / EBITDA | 15.87 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 21.13% |
| Return on Invested Capital | 13.20% |
| Return on Assets | 13.16% |
| Gross Margin | 97.97% |
| Operating Margin | 23.38% |
| Net Margin | 20.91% |
Related companies: COO · ELAN · ICLR · RDY · SMMT · SNN
Explore sector: Healthcare · Biotechnology
More sections of NBIX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks